Celebrate M*A*S*H 50 Anniversary! Alan Alda, Hawkeye Pierce, will personally autograph a M*A*S*H Script in your name. The episode "Dear Sigmund" was nominated for a writing Emmy and won for Directing.
Alan Alda has earned international recognition as an actor, writer and director. He has the distinction of being nominated for an Oscar (The Aviator), a Tony (Glengarry Glen Ross), and an Emmy (The West Wing) as well as publishing a bestselling book - all in the same year (2005). He also was honored with a SAG Lifetime Achievement Award.
Alda played Hawkeye Pierce on the classic and one of the highest rated shows in television history, M*A*S*H. He also wrote and directed many of the episodes. With 34 nominations, Alda received 6 Emmys. In addition to M*A*S*H and The West Wing, his television credits includes Jake's Women, ER, 30 Rock, Big C, Blacklist, Broad City, Horace and Peter and The Good Fight. He also hosted the award winning series Scientific American Frontiers, The Human Spark and Brains on Trial.
Alda’s other films include Crimes and Misdemeanors; Everyone Says I Love You; Flirting With Disaster; Manhattan Murder Mystery; And The Band Played On; Same Time, Next Year; Tower Heist; Wanderlust; Steven Spielberg’s Bridge of Spies; and, California Suite as well as The Seduction of Joe Tynan, which he wrote and The Four Seasons, Sweet Liberty, A New Life and Betsy’s Wedding, all of which he wrote and directed.
In addition to his Tony nomination for Glengarry Glen Ross, he was nominated for Jake’s Women and The Apple Tree. Other Broadway appearances include The Owl and the Pussycat, Purlie Victorious and Fair Game for Lovers for which he received a Theatre World Award. For over 20 years Alda has worked to help broaden the public’s understanding of science which includes funding The Alan Alda Center for Communicating Science at Stony Brook University.
Notice of Updated Buyer Terms of Use
We have recently updated our Buyer Terms of Use. We encourage you to review the revised terms to ensure continued understanding and compliance. By continuing to use our platform, you acknowledge and agree to the updated terms. View the updated Terms of Use